Stockscreener 앱 받기
6.89
1.77%
0.12
시간 외 거래:
6.84
-0.05
-0.73%
전일 마감가:
$6.77
열려 있는:
$6.77
하루 거래량:
66,721
Relative Volume:
0.38
시가총액:
$43.03M
수익:
$4.71M
순이익/손실:
$-90.32M
주가수익비율:
-0.7917
EPS:
-8.7032
순현금흐름:
$-85.19M
1주 성능:
+23.26%
1개월 성능:
+12.86%
6개월 성능:
-0.29%
1년 성능:
-9.16%
1일 변동 폭
$6.58
$6.97
1주일 범위
$5.73
$7.82
52주 변동 폭
$3.98
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
6.89 | 43.71M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-19 | 재개 | Jefferies | Buy |
| 2025-08-18 | 재개 | H.C. Wainwright | Buy |
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-09 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 재개 | Piper Sandler | Overweight |
| 2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 개시 | JP Morgan | Overweight |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
Industry Analysts Just Upgraded Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts By 68% - Moomoo
Aligos Therapeutics Company Profile & Introduction - Moomoo
Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History - Yahoo Finance
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - Investing News Network
Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China - TradingView
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com
Aligos Begins Testing a Chronic Hepatitis B Candidate in China - Stock Titan
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - simplywall.st
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.com
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics Inc (NASDAQ:ALGS) - intelligentinvestor.com.au
Cantor Fitzgerald Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Aligos earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Aligos Therapeutics Inc For: 6 August - Investing.com India
Aligos Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress - quiverquant.com
Aligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingView
ALGS: $27.8M licensing revenue drove a smaller Q2 loss; cash runway into Q4 2026, funding needed - TradingView
Aligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock Titan
Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingView
ALGS: Pipeline advances and licensing deals strengthen financials and outlook for HBV therapies - TradingView
ALIGOS THERAPEUTICS Q2 NET INCOME USD -1.504 MILLION - Moomoo
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Yahoo Finance
ALGS Q2'26 Earnings: EPS estimate is (1.09) USD - TradingView
Aligos Therapeutics, Inc. expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Earnings Preview: ALGS to Report Financial Results Pre-market on August 06 - moomoo.com
Aligos Therapeutics Inc expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Aligos Therapeutics to report Q2 2026 financial results on August 6, 2026 - Pluang
Aligos Therapeutics Inc (ALGS) Cash Flow - TradingKey
Aligos Therapeutics Inc (ALGS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALGS|Aligos Therapeutics Inc|Price:7.600|Chg%:+2.010 - TradingKey
ALGS|Aligos Therapeutics Inc|Price:4.075|Chg%:-0.005 - TradingKey
Aligos Therapeutics Inc (ALGS) Income Statement - TradingKey
Aligos Therapeutics Inc (ALGS) Balance Sheet - TradingKey
Aligos Therapeutics Inc (ALGS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aligos Therapeutics Inc (ALGS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aligos Therapeutics Inc (ALGS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALGS|Aligos Therapeutics Inc|Price:4.195|Chg%:+0.115 - TradingKey
Avoiding Lag: Real-Time Signals in (ALGS) Movement - Stock Traders Daily
ALGS Q2'26 Earnings: revenue estimate is 24.68M USD - TradingView
Aligos Therapeutics (ALGS) Holds Steady Near Support Amid Cautious TradingBlock Trade Flow - dars.gov.et
H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Aligos stock rating on trial enrollment - Investing.com
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Aligos Completes Phase 2 B-SUPREME Enrollment - t.co
Aligos Therapeutics stock is trending overnight: Here's what's going on with ALGS stock - MSN
Aligos Therapeutics Shares Decline 5.44% as Stock Tests Key Support LevelSymmetrical Triangle - dars.gov.et
Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment - Moomoo
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):